Triple antithrombotic therapy in cardiac patients: more questions than answers.
Many cardiac patients require combined antithrombotic therapy consisting of an anticoagulant and inhibition of platelet function. The most frequent indications are atrial fibrillation (AF) in combination with drug-eluting stent implantation and/or the presence of an acute coronary syndrome (ACS). Currently, the optimal combination of anticoagulants and anti-platelet therapy is unknown, but it is well established that the combination of regular doses and regimens as prescribed in AF or after ACS results in increased bleeding rates. In this review, we discuss the current literature and describe approaches to reduce the risk of bleeding hoping not to increase the rate of ischaemic events.
['Moser|Martin|M|', 'Olivier|Christoph B|CB|', 'Bode|Christoph|C|']
D000284:Administration, Oral D000925:Anticoagulants D002318:Cardiovascular Diseases D004334:Drug Administration Schedule D004359:Drug Therapy, Combination D054855:Drug-Eluting Stents D004617:Embolism D005343:Fibrinolytic Agents D006083:Graft Occlusion, Vascular D006470:Hemorrhage D006801:Humans D062645:Percutaneous Coronary Intervention D017410:Practice Guidelines as Topic D057285:Precision Medicine D058921:Purinergic P2Y Receptor Antagonists D016032:Randomized Controlled Trials as Topic D020521:Stroke D014812:Vitamin K
Antithrombotic therapy Platelets Atrial fibrillation Acute coronary syndrome Triple therapy